新闻情绪
AIStockmoo 评分
| 价值 30% | -3.3 |
| 资本回报低于资本成本。资本回报下降。 参考 | |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | 1.7 |
| 过去一年没有明确趋势。股价略低于52周高点。 参考 | |
| 上升趋势:股价位于均线之上,均线向上。股价接近均线。上涨日成交量较大。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.6 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 20% | 2.8 |
| 机构在最新13F申报中净+3.45%的股份:45家增持,67家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-19.3%,回补天数1天(FINRA)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 高于中期趋势线。 参考 | |
| 股价高于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向上。短期动能上升。 参考 | |
| 股价接近支撑位。支撑与阻力水平趋升。 参考 | |
| 最终评分 | 0.14 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Pulmonx Corporation | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| LUNG | - | - | - | 3.48 | 0.1 |
| SMLR | 368 M | - | 7.48 | - | -0.4 |
| BSGM | 169 M | - | - | 36.58 | -0.1 |
| IINN | 19 M | - | - | 13.64 | -0.4 |
| PTHL | 15 M | - | - | 2.19 | 0.0 |
| RSLS | 4 M | - | 0.019 | 30.42 | -0.8 |
|
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 4.40% |
| 机构持股比例 | 90.83% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Primecap Management Co/Ca/ | 30 Sep 2026 | 4,408,431 |
| Soleus Capital Management, L.P. | 30 Sep 2026 | 3,088,323 |
| Almitas Capital Llc | 30 Sep 2026 | 1,080,038 |
| Parkman Healthcare Partners Llc | 30 Sep 2026 | 853,986 |
| Braidwell Lp | 30 Sep 2026 | 752,541 |
| D. E. Shaw & Co., Inc. | 30 Sep 2026 | 740,868 |
| Marshall Wace, Llp | 30 Sep 2026 | 660,466 |
| Acadian Asset Management Llc | 30 Sep 2026 | 522,987 |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 67.43%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 45 | 4,687,719 |
| 减持 | 67 | 3,808,268 |
| 新建仓 | 17 | 1,217,235 |
| 清仓 | 24 | 578,840 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 787,512 | 1.0 |
| 15 Oct 2026 | 698,644 | 2.5 |
| 30 Sep 2026 | 802,733 | 3.2 |
| 15 Sep 2026 | 847,842 | 2.5 |
| 31 Aug 2026 | 976,237 | 2.6 |
| 14 Aug 2026 | 1,066,574 | 1.2 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare… |
| 17 Nov 2026 | Yahoo Finance |
Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
Study demonstrates potential to enable Zephyr® Valve treatment for selected severe COPD/emphysema patients previously ineligible due to collateral ventilationREDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in… |
| 08 Nov 2026 | Yahoo Finance |
Pulmonx: 3 Key Takeaways for Long-Term Investors
Gross margins above 75% and a narrowing path to cash flow breakeven give the turnaround real financial teeth. |
| 30 Oct 2026 | Yahoo Finance |
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
| 28 Oct 2026 | Yahoo Finance |
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity… |
| 27 Oct 2026 | Yahoo Finance |
Pulmonx (LUNG) Q3 2026 Earnings Call Transcript
Revenue returned to growth while losses narrowed significantly on cost discipline. |
| 27 Oct 2026 | Yahoo Finance |
What Pulmonx (LUNG) Said on Its Q3 Earnings Call
Pulmonx (NASDAQ:LUNG) reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market. Total worldwide revenue for the quarter ended Sept. 30 was $22… |
| 27 Oct 2026 | Yahoo Finance |
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +26.92% and +3.75%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 27 Oct 2026 | Yahoo Finance |
Pulmonx Reports Third Quarter 2026 Financial Results
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026. Recent Highlights… |
| 13 Oct 2026 | Yahoo Finance |
Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday… |
| 03 Sep 2026 | Yahoo Finance |
Pulmonx Shares Fall Following Recent Gains
Pulmonx (NASDAQ:LUNG) shares fell 10. 1% to $2… |
| 01 Sep 2026 | Yahoo Finance |
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025… |
| 26 Aug 2026 | Yahoo Finance |
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event? |
| 显示更多 | ||
技术形态 中期
AI 技术分析
投资组合